Live Attenuated Rev-Independent Nef-SIV Enhances Acquisition of Heterologous SIVsmE660 in Acutely Vaccinated Rhesus Macaques

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Byrareddy, Siddappa N ^a,b,d   Ayash Rashkovsky, Mila ^a,b   Kramer, Victor G ^a   Lee, Sandra J ^a   Correll, Mick ^a   Novembre, Francis J ^c,d   Villinger, Francois ^c,d   Johnson, Welkin E ^e   von Gegerfelt, Agneta ^d,f   Felber, Barbara K ^d,f   Ruprecht, Ruth M ^a,b,g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON COLLEGE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; LIVE VACCINE; NEF PROTEIN; REV PROTEIN; VIRUS VACCINE;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOREGULATION; INNATE IMMUNITY; NEWBORN; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SUPERINFECTION; UPREGULATION; VACCINATION; VIRUS STRAIN;

ANIMALS; GENE EXPRESSION PROFILING; GENE PRODUCTS, REV; IMMUNITY, INNATE; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VACCINES, ATTENUATED; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIREMIA;

EID: 84884746235     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075556     Document Type: Article

References (66)

1. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL, (2010) HIV vaccines: lessons learned and the way forward. Curr Opin HIV Aids 5: 428-434. doi:10.1097/COH.0b013e32833d17ac. PubMed: 20978385.
2. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC, (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941. doi:10.1126/science.1470917. PubMed: 1470917.
3. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19-23. doi:10.1038/ni1296. PubMed: 16357854.
4. Lallemant M, McIntosh K, Jourdain G, Le Coeur S, Vithayasai V, et al. (1998) Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. N Engl J Med 338: 831-840; author reply 950863895086379508636.
5. Whitney JB, Ruprecht RM, (2004) Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 17: 17-26. doi:10.1097/00001432-200402000-00004. PubMed: 15090885.
6. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC, (1996) Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 70: 3724-3733. PubMed: 8648707.
7. Berry N, Ham C, Mee ET, Rose NJ, Mattiuzzo G, et al. (2011) Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLOS ONE 6: e23092. doi:10.1371/journal.pone.0023092. PubMed: 21853072.
8. Nilsson C, Mäkitalo B, Thorstensson R, Norley S, Binninger-Schinzel D, et al. (1998) Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12: 2261-2270. doi:10.1097/00002030-199817000-00006. PubMed: 9863867.
9. Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, et al. (2010) Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 84: 9190-9199. doi:10.1128/JVI.00041-10. PubMed: 20592091.
10. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, et al. (2008) Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 205: 2537-2550. doi:10.1084/jem.20081524. PubMed: 18838548.
11. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, et al. (1999) Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73: 8356-8363. PubMed: 10482586.
12. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, et al. (2003) Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 77: 6823-6835. doi:10.1128/JVI.77.12.6823-6835.2003. PubMed: 12768002.
13. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, et al. (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267: 1820-1825. doi:10.1126/science.7892606. PubMed: 7892606.
14. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5: 194-203. doi:10.1038/5557. PubMed: 9930868.
15. Buckley KA, Li PL, Khimani AH, Hofmann-Lehmann R, Liska V, et al. (2003) Convergent evolution of SIV env after independent inoculation of rhesus macaques with infectious proviral DNA. Virology 312: 470-480. doi:10.1016/S0042-6822(03)00262-9. PubMed: 12919751.
16. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, et al. (1998) Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 72: 1431-1437. PubMed: 9445045.
17. Gibbs JS, Regier DA, Desrosiers RC, (1994) Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 10: 607-616. doi:10.1089/aid.1994.10.607. PubMed: 7917522.
18. Kestler HW 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, et al. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662. doi:10.1016/0092-8674(91)90097-I. PubMed: 2032289.
19. Ruprecht RM, Baba TW, Liska V, (1996) Attenuated HIV Vaccine: Caveats. Science 271: 1790b-1791b. doi:10.1126/science.271.5257.1790b. PubMed: 17812356.
20. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, et al. (2003) Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17: 157-166. doi:10.1097/00002030-200301240-00004. PubMed: 12545074.
21. Birch MR, Learmont JC, Dyer WB, Deacon NJ, Zaunders JJ, et al. (2001) An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol 22: 263-270. doi:10.1016/S1386-6532(01)00198-6. PubMed: 11564591.
22. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, et al. (1999) Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 340: 1715-1722. doi:10.1056/NEJM199906033402203. PubMed: 10352163.
23. von Gegerfelt A, Felber BK, (1997) Replacement of posttranscriptional regulation in SIVmac239 generated a Rev-independent infectious virus able to propagate in rhesus peripheral blood mononuclear cells. Virology 232: 291-299. doi:10.1006/viro.1997.8567. PubMed: 9191842.
24. Smulevitch S, Bear J, Alicea C, Rosati M, Jalah R, et al. (2006) RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs. Retrovirology 3: 6.
25. von Gegerfelt AS, Liska V, Li PL, McClure HM, Horie K, et al. 2002) Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. J Virol 76: 96-104.
26. von Gegerfelt AS, Liska V, Ray NB, McClure HM, Ruprecht RM, et al. (1999) Persistent infection of rhesus macaques by the rev-independent Nef(-) simian immunodeficiency virus SIVmac239: replication kinetics and genomic stability. J Virol 73: 6159-6165. PubMed: 10364376.
27. von Gegerfelt AS, Alicea C, Valentin A, Morrow M, van Rompay KK, et al. (2006) Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res Hum Retroviruses 22: 516-528.
28. Sugimoto C, Watanabe S, Naruse T, Kajiwara E, Shiino T, et al. (2010) Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. PLOS ONE 5: e11678. doi:10.1371/journal.pone.0011678. PubMed: 20652030.
29. Schmitz JE, Johnson RP, McClure HM, Manson KH, Wyand MS, et al. (2005) Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 79: 8131-8141. doi:10.1128/JVI.79.13.8131-8141.2005. PubMed: 15956558.
30. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, et al. (1998) Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 72: 7501-7509. PubMed: 9696847.
31. Vlasak J, Ruprecht RM, (2006) AIDS vaccine development and challenge viruses: getting real. AIDS 20: 2135-2140. doi:10.1097/QAD.0b013e328010beb5. PubMed: 17086052.
32. Hofmann-Lehmann R, Swenerton RK, Liska V, Leutenegger CM, Lutz H, et al. (2000) Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retrovir 16: 1247-1257. doi:10.1089/08892220050117014. PubMed: 10957722.
33. Cline AN, Bess JW, Piatak M Jr., Lifson JD, (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303-312. doi:10.1111/j.1600-0684.2005.00128.x. PubMed: 16128925.
34. Reynolds MR, Sacha JB, Weiler AM, Borchardt GJ, Glidden CE, et al. (2011) The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol 85: 9637-9640. doi:10.1128/JVI.05074-11. PubMed: 21734037.
35. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, et al. (2013) DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A 110: 2975-2980. doi:10.1073/pnas.1215393110. PubMed: 23359688.
36. Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, et al. (2011) Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 204: 164-173. doi:10.1093/infdis/jir071. PubMed: 21628671.
37. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, et al. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 3: 81ra36. PubMed: 21543722.
38. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. (2010) TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLOS Biol 8.
39. Lim SY, Rogers T, Chan T, Whitney JB, Kim J, et al. (2010) TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLOS Pathog 6: e1000738. PubMed: 20107597.
40. Almond N, Kent K, Cranage M, Rud E, Clarke B, et al. (1995) Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345: 1342-1344. doi:10.1016/S0140-6736(95)92540-6. PubMed: 7752758.
41. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, et al. (1999) Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73: 4952-4961. PubMed: 10233957.
42. Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, et al. (1997) Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 71: 7711-7718. PubMed: 9311855.
43. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature 417: 95-98. doi:10.1038/417095a. PubMed: 11986671.
44. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, et al. (2000) Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med 191: 1921-1931. doi:10.1084/jem.191.11.1921. PubMed: 10839807.
45. Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, et al. (2011) Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 29: 6742-6754. doi:10.1016/j.vaccine.2010.12.056. PubMed: 21195080.
46. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, et al. (2012) Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 18: 1673-1681. doi:10.1038/nm.2934. PubMed: 22961108.
47. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, et al. (2009) Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182: 3718-3727. doi:10.4049/jimmunol.0803115. PubMed: 19265150.
48. Forthal DN, Moog C, (2009) Fc receptor-mediated antiviral antibodies. Curr Opin HIV Aids 4: 388-393. doi:10.1097/COH.0b013e32832f0a89. PubMed: 20048702.
49. Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, et al. (2011) Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 57: 238-244. doi:10.1097/QAI.0b013e31821acb5. PubMed: 21860356.
50. Crostarosa F, Aravantinou M, Akpogheneta OJ, Jasny E, Shaw A, et al. (2009) A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLOS ONE 4: e8060. doi:10.1371/journal.pone.0008060. PubMed: 20011586.
51. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73-83. doi:10.1097/01.aids.0000198081.09337.a7. PubMed: 16327322.
52. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, et al. (2009) Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 199: 958-964. doi:10.1086/597208. PubMed: 19220143.
53. Chenine AL, Shai-Kobiler E, Steele LN, Ong H, Augostini P, et al. (2008) Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. PLoS Negl Trop. Drosophila Inf Serv 2: e265.
54. Siddappa NB, Hemashettar G, Shanmuganathan V, Semenya AA, Sweeney ED, et al. (2011) Schistosoma mansoni enhances host susceptibility to mucosal but not intravenous challenge by R5 Clade C SHIV. PLoS Negl Trop. Drosophila Inf Serv 5: e1270.
55. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893. doi:10.1016/S0140-6736(08)61591-3. PubMed: 19012954.
56. Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, et al. (2011) Impact of Herpes Simplex Virus Type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step Study). J Acquir Immune Defic Syndr.
57. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905. doi:10.1016/S0140-6736(08)61592-5. PubMed: 19012957.
58. Stauber RH, Horie K, Carney P, Hudson EA, Tarasova NI, et al. (1998) Development and applications of enhanced green fluorescent protein mutants. BioTechniques 24: 462-471. 9526659.
59. Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, et al. (2011) Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLOS ONE 6: e22010. doi:10.1371/journal.pone.0022010. PubMed: 21799765.
60. Mühl T, Krawczak M, Ten Haaft P, Hunsmann G, Sauermann U, (2002) MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 169: 3438-3446. PubMed: 12218167.
61. Sauermann U, Siddiqui R, Suh YS, Platzer M, Leuchte N, et al. (2008) Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes Immun 9: 69-80. doi:10.1038/sj.gene.6364448. PubMed: 18094710.
62. Carey VJ, Gentry J, Whalen E, Gentleman R, (2005) Network structures and algorithms in Bioconductor. Bioinformatics 21: 135-136. doi:10.1093/bioinformatics/bth458. PubMed: 15297301.
63. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15. doi:10.1093/nar/gng015. PubMed: 12582260.
64. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80. doi:10.1186/gb-2004-5-10-r80. PubMed: 15461798.
65. Clevert DA, Mitterecker A, Mayr A, Klambauer G, Tuefferd M, et al. (2011) cn.FARMS: a latent variable model to detect copy number variations in microarray data with a low false discovery rate. Nucleic Acids Res, 39: e79-. PubMed: 21486749.
66. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. BioTechniques 34: 374-378. PubMed: 12613259.